儿童和青少年代谢相关脂肪性肝病研究进展*

doi:10.3969/j.issn.1672-5069.2024.04.003

Abstract

Liu Yali, Zhang Jing. Child and adolescent metabolic dysfunction-associated fatty liver disease:current state of the art and perspectives[J]. Journal of Practical Hepatology, 2024, 27(4): 488-491.

[1] Eslam M, Alkhouri N, Vajro P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol,2021,6(10):864-873.
[2] Abarca-Gómez L, Abdeen Z A, Hamid Z A, et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet,2017,390(10113):2627-2642.
[3] Le M, Le D, Baez T C, et al. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol,2023,79(2):287-295.
[4] Eslam M, Newsome P N, Sarin S K, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol,2020,73(1):202-209.
[5] Eslam M, Sanyal A J, George J. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology,2020,158(7):1999-2014.
[6] Kanwal F, Neuschwander-Tetri B A, Loomba R, et al. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology,2024,79(5):1212-1219.
[7] Rinella M E, Lazarus J V, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol,2023,79(6):1542-1556.
[8] 范建高,李小英. NAFLD更名MAFLD、MASLD:背景、异同、对策. 中华肝脏病杂志,2023,28(8):789-792.
[9] Nobili V, Pinzani M. Alcoholic and non-alcoholic fatty liver in adolescents: a worrisome convergence. Alcohol Alcohol,2011,46(5):627-629.
[10] Hegarty R, Deheragoda M, Fitzpatrick E, et al. Paediatric fatty liver disease (PeFLD): All is not NAFLD - Pathophysiological insights and approach to management. J Hepatol,2018,68(6):1286-1299.
[11] 濮佳琦,王森杰,薛初晴,等. 儿童脂肪性肝病命名探析. 中华儿科杂志,2023,32(2):104-107.
[12] Zhang L, El-Shabrawi M, Baur L A, et al. An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease. Med,2024[ahead of print] .
[13] Anderson E L, Howe L D, Fraser A, et al. Weight trajectories through infancy and childhood and risk of non-alcoholic fatty liver disease in adolescence: the ALSPAC study. J Hepatol,2014,61(3):626-632.
[14] Rupasinghe K, Hind J, Hegarty R. Updates in metabolic dysfunction-associated fatty liver disease (MAFLD) in Children. J Pediatr Gastroenterol Nutr,2023,77(5):583-591.
[15] Santoro N, Kursawe R, D'Adamo E, et al. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology,2010,52(4):1281-1290.
[16] Jarasvaraparn C, Vilar-Gomez E, Yates K P, et al. Age, BMI, and type 2 diabetes modify the relationship between PNPLA3 and advanced fibrosis in children and adults with NAFLD. Clin Gastroenterol Hepatol,2024,22(5):1024-1036.
[17] Walker R W, Belbin G M, Sorokin E P, et al. A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank. J Hepatol,2020,72(6):1070-1081.
[18] Nobili V, Alisi A, Valenti L, et al. NAFLD in children: new genes, new diagnostic modalities and new drugs. Nat Rev Gastroenterol Hepatol,2019,16(9):517-530.
[19] Oh D Y, Talukdar S, Bae E J, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell,2010,142(5):687-698.
[20] Marzuillo P, Grandone A, Conte M, et al. Novel association between a nonsynonymous variant (R270H) of the G-protein-coupled receptor 120 and liver injury in children and adolescents with obesity. J Pediatr Gastroenterol Nutr,2014,59(4):472-475.
[21] Ohtani N, Kamiya T, Kawada N. Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond. Hepatol Commun,2023,7(9):e241.
[22] 中华医学会儿科学分会内分泌遗传代谢学组,中华医学会儿科学分会消化学组,中华医学会儿科学分会青春期医学专业委员会,等. 儿童非酒精性脂肪肝病诊断与治疗专家共识. 中国实用儿科杂志,2018,33(7):487-492.
[23] Vos M B, Abrams S H, Barlow S E, et al. NASPGHAN Clinical Practice Guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr,2017,64(2):319-334.
[24] Di Sessa A, Guarino S, Umano G R, et al. Uric acid in pediatric MASLD definition: Is it time to implement diagnostic criteria? J Hepatol,2024,79(6):1-2.
[25] Wang C W, Huang P C, Dai C Y, et al. Comparative evaluation of pediatric fatty liver disease criteria: MASLD, ESPGHAN, NASPGHAN, and NAFLD - identifying the optimal pediatric label. J Hepatol,2024,80(4):e157-e159.
[26] Draijer L, Benninga M, Koot B. Pediatric NAFLD: an overview and recent developments in diagnostics and treatment. Expert Rev Gastroenterol Hepatol,2019,13(5):447-461.
[27] Anania C, Perla F M, Olivero F, et al. Mediterranean diet and nonalcoholic fatty liver disease. World J Gastroenterol,2018,24(19):2083-2094.
[28] Yaskolka M A, Rinott E, Tsaban G, et al. Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial. Gut,2021,70(11):2085-2095.
[29] Violi F, Cangemi R. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med,2010,363(12):1185-1186.
[30] Lavine J E, Schwimmer J B, Van Natta M L, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA,2011,305(16):1659-1668.
[31] Ji L, Dong X, Li Y, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial. Diabetes Obes Metab,2021,23(2):404-414.
[32] Weghuber D, Barrett T, Barrientos-Perez M, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med,2022,387(24):2245-2257.
[33] 任璐,张晓伟,刘娜. 粪菌移植治疗代谢相关脂肪性肝病的理论基础和研究进展. 中华临床营养杂志,2023,18(4):244-250.

Child and adolescent metabolic dysfunction-associated fatty liver disease:current state of the art and perspectives

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Chen Sitong, Wei Xiaodie, Wei Xinhuan, et al. Diagnosis and treatment of patients with metabolic dysfunction-associated steatotic liver disease [J]. Journal of Practical Hepatology, 2024, 27(4): 481-483.
[2]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease(Version 2024) [J]. Journal of Practical Hepatology, 2024, 27(4): 494-510.
[3]	Xue Lina, Zhu Guobing, Wu Linlin, et al. Virological response to tenofovir alafenamide in patients with low-level viremia chronic hepatitis B after entecavir treatment [J]. Journal of Practical Hepatology, 2024, 27(4): 519-522.
[4]	Luo Hongxia, Li Jingqiu, Li Yuanyuan, et al. Magnetic resonance proton density fat fraction in overweight/obese children with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2024, 27(4): 527-530.
[5]	Ren Hao, Xiong Qingfang. Diagnostic performance of fournoninvasive detection indexes in predicting liver cirrhosis in patients with autoimmune liver diseases [J]. Journal of Practical Hepatology, 2024, 27(4): 535-538.
[6]	Ke Haixia, Zhang Jiaozhen, Meng Xialing, et al. Assessment of bacterial infection by serum CRP and sTREM-1 levels in patients with hepatitis B virus-associated acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2024, 27(4): 555-558.
[7]	Zhao Weibo, Wang Yuan, Kong Lingjia, et al. Effect of balloon-compression endoscopic injection sclerotherapy in the treatment of patients with decompensated stage of hepatitis B cirrhosis and esophageal varices [J]. Journal of Practical Hepatology, 2024, 27(4): 559-562.
[8]	Tang Zeyu, Gu Fei, Zhou Jianwen, et al. Diagnostic efficacy of CT parameters and FIB-4 and serum VEGF levels in predicting esophageal varices in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(4): 579-582.
[9]	Xia Lipeng, Chu Yuxuan, Zhao Rusheng. Contrast-enhanced MRI and IVIM-DWI in the diagnosis of patients with small hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(4): 587-590.
[10]	Tian Chunyan, Luo Li, Cao Xueling, et al. Differential diagnosis of hepatocellular carcinoma and hepatic hemangioma by contrast-enhanced ultrasonography [J]. Journal of Practical Hepatology, 2024, 27(4): 603-606.
[11]	Wang Zhenghua, Wang Mingda, Zhang Xiaoqian. Qualitative diagnosis of hepatic space-occupying lesions by contrast-enhanced ultrasonography [J]. Journal of Practical Hepatology, 2024, 27(4): 607-610.
[12]	Sui Hu, Mao Jia, Chen Lu, et al. Application of CT quantitative parameters in the differentiation of hepatocellular carcinoma from focal nodular hyperplasia [J]. Journal of Practical Hepatology, 2024, 27(4): 611-614.
[13]	Liang Lei, Li Yingdong, Gao Yang, et al. Clinical and imaging feature in patients with focal nodular hyperplasia of the liver [J]. Journal of Practical Hepatology, 2024, 27(4): 615-618.
[14]	Wu Helin, Wu Huihui, Shen Chunlin. Feature of spiral CT multi-phase enhancement of inflammatory pseudotumor of the liver: An analysis of 32 cases [J]. Journal of Practical Hepatology, 2024, 27(4): 623-626.
[15]	He Zhi, Qu Zedong, Liu Jie, et al. Application of magnetic resonance cholangiopancreatography and diffusion-weighted imaging in the diagnosis of infants with biliary atresia [J]. Journal of Practical Hepatology, 2024, 27(4): 631-634.